INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in RCI Hospitality Holdings, Inc. of Class Action Lawsuit and Upcoming Deadlines - RICK

NEW YORK, Pomerantz LLP announces that a class action lawsuit has been filed against RCI Hospitality Holdings, Inc. (“RCI” or the “Company”) (NASDAQ: RICK). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether RCI and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until November 20, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired RCI securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com        

[Click here for information about joining the class action]

On September 16, 2025, New York’s Office of the Attorney General announced the indictment of certain top executives of RCI, alleging that its investigation “revealed that RCI executives bribed an auditor with the New York Department of Taxation and Finance (DTF) to avoid paying over $8 million in sales taxes to New York City and the state from 2010 to 2024.” 

On this news, RCI’s stock price fell $25.80 per share, or 24.83%, over the following two trading sessions, to close at $25.80 per share on September 17, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors in Sina Corporation of Class Action Lawsuit and Upcoming Deadlines - SINA

NEW YORK, Pomerantz LLP announces that a securities fraud class action lawsuit has been filed against Sina Corporation (“Sina” or the “Company”) (formerly NASDAQ: SINA) and certain of its executive officers (collectively, “Defendants”) on behalf of investors who sold Sina ordinary shares, including those that sold into the Merger (defined below), between October 13, 2020 and March 22, 2021, inclusive (the “Class Period”). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether Sina and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until November 18, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you sold Sina ordinary shares during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com        

[Click here for information about joining the class action]

This action concerns the Defendants’ fraudulent scheme to depress the value of Sina ordinary shares to avoid paying a fair price to Sina’s shareholders in connection with a take-private acquisition by a buyer group controlled by Sina’s Chief Executive Officer (the “Merger”).  Defendants executed this scheme by misrepresenting and/or omitting material information within and from Sina’s proxy materials in connection with the Merger that were necessary for shareholders to make an informed decision concerning whether to vote in favor of the Merger.  Specifically, Defendants failed to disclose that: (1) Defendants concealed the true value of the Company’s investment in TuSimple Holdings, Inc. at the time of the Merger; and (2) in turn, the offer of $43.30 per ordinary share as consideration for the Merger substantially shortchanged the true value of Sina ordinary shares. 

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in KBR, Inc. of Class Action Lawsuit and Upcoming Deadlines - KBR

NEW YORK, Pomerantz LLP announces that a class action lawsuit has been filed against KBR, Inc. (“KBR” or the “Company”) (NYSE: KBR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether KBR and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until November 18, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired KBR securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com        

[Click here for information about joining the class action]

On June 19, 2025, HomeSafe Alliance (“HomeSafe”), a KBR joint venture, announced receipt of “a notice from the U.S. Department of Defense’s Transportation Command (TRANSCOM) terminating the Global Household Goods Contract, which HomeSafe won in 2021 to transform the military move system for the benefit of service members and their families.”  Then, on June 20, 2025, KBR issued a substantively similar press release about the termination of the Global Household Goods Contract. 

On this news, KBR’s stock price fell $3.85 per share, or 7.29%, to close at $48.93 per share on June 20, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

 Attorney advertising.  Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quanex Building Products Corporation of Class Action Lawsuit and Upcoming Deadlines - NX

NEW YORK, Pomerantz LLP announces that a class action lawsuit has been filed against Quanex Building Products Corporation (“Quanex” or the “Company”) (NYSE: NX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether Quanex and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until November 18, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Quanex securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com        

[Click here for information about joining the class action]

On September 4, 2025, after the market closed, Quanex announced its financial results for the third quarter of its 2025 fiscal year.  Quanex disclosed, among other things, that ongoing “operational issues related to the legacy Tyman window and door hardware business in Mexico” had “impacted results more than expected[.]”  Quanex also disclosed that it was “adjusting for lower expected volumes and pushing oug the timing of when [it] expect[s] to realize procurement savings” from integration of the Tyman business.  Then, on September 5, 2025, Quanex held an earnings call to discuss the quarter’s financial results.  During the call, Chief Executive Officer George Wilson explained that the operational challenges at Tyman “negatively impacted EBITDA in the Hardware Solutions segment by almost $5 million in the third quarter alone.”  Wilson explained that the issue had been “identified midyear” and described the systems used to “anticipate and plan for tooling repairs” as significantly deficient. 

On this news, Quanex’s stock price fell $2.73 per share, or 13.06%, to close at $18.18 per share on September 5, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Cytokinetics, Incorporate of Class Action Lawsuit and Upcoming Deadlines – CYTK

NEW YORK, Pomerantz LLP announces that a class action lawsuit has been filed against Cytokinetics, Incorporate (“Cytokinetics” or the “Company”) (NASDAQ: CYTK).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 

The class action concerns whether Cytokinetics and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

You have until November 17, 2025, to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Cytokinetics securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.          

[Click here for information about joining the class action]  

On March 10, 2025, Cytokinetics disclosed that the U.S. Food and Drug Administration (“FDA”) had decided not to convene an advisory committee meeting to review the Company’s New Drug Application (“NDA”) for aficamten.  On May 1, 2025, Cytokinetics announced that the FDA had extended the Prescription Drug User Fee Act action date for aficamten’s NDA from September 26, 2025 to December 26, 2025 in order to review a Risk Evaluation and Mitigation Strategy (“REMS”) submitted at the FDA’s request after the initial NDA filing, thereby disclosing that the Company had not included a REMS in the original NDA. 

On this news, Cytokinetics’ stock price fell $5.57 per share, or 12.98%, to close at $37.35 per share on May 2, 2025. 

Then, on May 6, 2025, Chief Executive Officer Robert I. Blum acknowledged that Cytokinetics had multiple pre-NDA meetings with the FDA to discuss safety monitoring and risk mitigation but chose to submit the NDA without a REMS, relying on labeling and voluntary education materials. 

On this news, Cytokinetics’ stock price fell $2.70 per share, or 7.36%, to close at $33.97 per share on May 6, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com

Attorney advertising.  Prior results do not guarantee similar outcomes.    

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in VF Corporation of Class Action Lawsuit and Upcoming Deadlines – VFC

NEW YORK, Pomerantz LLP announces that a class action lawsuit has been filed against VF Corporation (“VFC” or the “Company”) (NYSE: VFC).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 

The class action concerns whether VFC and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

You have until November 12, 2025, to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired VFC securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.          

[Click here for information about joining the class action]  

On May 21, 2025, VFC reported its fourth quarter and full-year fiscal 2025 financial results, highlighting a significant decline in the growth trajectory for its Vans brand, which fell from an 8% loss in the previous quarter to a 20% loss in the fourth quarter.  VFC described these results and below-expectation guidance as “a direct effect of deliberately reduced revenue to eliminate unprofitable or unproductive businesses.” 

Following this news, VFC’s stock price fell $2.21 per share, or 15.8%, to close at $12.15 per share on May 21, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com

Attorney advertising.  Prior results do not guarantee similar outcomes.    

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Lantheus Holdings, Inc. of Class Action Lawsuit and Upcoming Deadlines - LNTH

NEW YORK, Pomerantz LLP announces that a class action lawsuit has been filed against Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether Lantheus and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until November 10, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Lantheus securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.         

[Click here for information about joining the class action]

On May 7, 2025, Lantheus reported its financial results for the first quarter of 2025, which fell short of market expectations.  Lantheus announced, among other items, that sales of its radiopharmaceutical oncology product Pylarify had decreased year-over-year due to an alleged “temporal competitive disruption.”  The Company further reduced its previous full-year projections due to Pylarify’s shortfall. 

On this news, Lantheus’s stock price fell $24.35 per share, or 23.23%, to close at $80.49 per share on May 7, 2025. 

Then, on August 6, 2026, Lantheus announced disappointing second quarter 2025 results, revealing earnings-per-share (“EPS”) and revenue figures that missed expectations.  Once again, Lantheus significantly lowered growth expectations for Pylarify, sales of which had fallen 8.3% year-over-year, and further lowered the Company’s full-year 2025 projections.  Lantheus attributed its results in part to ongoing competition, which impacted Pylarify’s pricing dynamics. 

On this news, Lantheus’s stock price fell $20.76 per share, or 28.58%, to close at $51.87 per share on August 6, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Fly-E Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - FLYE

NEW YORK, Pomerantz LLP announces that a class action lawsuit has been filed against Fly-E Group, Inc. (“Fly-E” or the “Company”) (NASDAQ: FLYE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether Fly-E and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until November 7, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Fly-E securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.         

[Click here for information about joining the class action]

On August 14, 2025, Fly-E filed a form NT 10-Q: Notification of inability to timely file Form 10-Q for the first quarter of fiscal year 2026 revealing a substantial decrease of 32% in net revenues “primarily driven by a decrease in total units sold.”  In pertinent part, the Company attributed the decline to “recent lithium-battery accidents involving E-Bikes and E-Scooters.” 

On this news, Fly-E’s stock price fell $6.76 per share, or 87.11%, to close at $1.00 per share on August 15, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Corporation of Class Action Lawsuit and Upcoming Deadlines - QMCO

NEW YORK, Pomerantz LLP announces that a class action lawsuit has been filed against Quantum Corporation (“Quantum” or the “Company”)(NASDAQ: QMCO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether Quantum and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until November 3, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Quantum securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com        

[Click here for information about joining the class action]

On June 30, 2025, Quantum disclosed in a filing with the U.S. Securities and Exchange Commission (“SEC”) that it would postpone the filing of its Annual Report because it was in the process of reviewing its revenue recognition accounting practices. 

 On this news, Quantum’s stock price fell $1.00 per share, or 10.03%, to close at $8.97 per share on July 1, 2025.  

Then, on August 8, 2025, Quantum filed a report with the SEC, announcing that the Company’s financials for the third quarter of 2024 could not be relied upon and would be restated to show a new decrease of approximately $3.9 million in revenue, and that there were deficiencies in the Company’s internal control over financial reporting and the Company’s disclosure controls and procedures that constituted material weaknesses as of December 31, 2024 and March 31, 2025.  

On this news, Quantum’s stock price fell $0.14 per share, or 1.85%, to close at $7.43 per share on August 11, 2025.  

Finally, on August 18, 2025, Quantum announced the resignation of its Chief Financial Officer Lewis Moorehead amid an internal accounting review related to its revenue recognition practices.  

On this news, Quantum’s stock price fell $0.61 per share, or 8.2%, to close at $6.83 per share on August 19, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Tronox Holdings Plc of Class Action Lawsuit and Upcoming Deadlines - TROX

NEW YORK, Pomerantz LLP announces that a class action lawsuit has been filed against Tronox Holdings Plc (“Tronox” or the “Company”) (NYSE: TROX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether Tronox and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until November 3, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Tronox securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.         

[Click here for information about joining the class action]

On July 30, 2025, Tronox announced its financial results for the second quarter of fiscal 2025, revealing a significant reduction in sales of the Company’s TiO2 products for the quarter.  The Company attributed the decline to “softer than anticipated coatings season and heightened competitive dynamics.”  As a result of the setback in sales, Tronox revised its 2025 financial outlook, lowering its full-year revenue guidance and reducing its dividend by 60%. 

On this news, Tronox’s stock price fell $1.95 per share, or 37.94%, to close at $3.19 per share on July 31, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Semler Scientific, Inc. of Class Action Lawsuit and Upcoming Deadlines - SMLR

NEW YORK, Pomerantz LLP announces that a class action lawsuit has been filed against Semler Scientific, Inc. (“Semler” or the “Company”) (NASDAQ: SMLR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether Semler and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until October 28, 2025, to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Semler securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.         

[Click here for information about joining the class action]

On February 28, 2025, Semler filed its annual report for full year 2024 and disclosed that “there is a risk that [U.S. Department of Justice (‘DOJ’)] will file a complaint or complaint in intervention in a civil False Claims Act lawsuit seeking damages for tests performed using our device[.]”  The Company also revealed it had received an initial civil investigative demand from the DOJ in July 2017 regarding Semler’s claims for reimbursement related to its peripheral artery disease QuantaFlo device.  The Company further stated that it had participated in settlement discussions with the DOJ in February 2025, which were unsuccessful. 

On this news, Semler’s stock price fell $4.03 per share, or 9.4%, to close at $38.89 per share on March 3, 2025. 

Then, on April 15, 2025, Semler announced that it had reached an agreement with the DOJ “in principle on payment of $29.75 million to settle all claims.” 

On this news, Semler’s stock price fell $3.40 per share, or 9.88%, to close at $31.00 per share on April 16, 2025. 

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in LifeMD, Inc. of Class Action Lawsuit and Upcoming Deadlines - LFMD

NEW YORK, Pomerantz LLP announces that a class action lawsuit has been filed against LifeMD, Inc. (“LifeMD” or the “Company”) (NASDAQ: LFMD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether LifeMD and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until October 27, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired LifeMD securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.         

[Click here for information about joining the class action]

On August 5, 2025, after the market closed, the Company issued a press release entitled “LifeMD Reports Second Quarter 2025 Results.”  This announcement quoted Chief Financial Officer Marc Benathen as stating that due to “some temporary challenges facing our Rex MD business,” which he claimed were “largely resolved,” that the Company was “revising our full year 2025 guidance for revenue and adjusted EBITDA to reflect the full-year impact of these issues, while still anticipating strong year-over-year growth in both metrics.” 

On this news, LifeMD’s stock price fell $5.31 per share, or 44.85%, to close at $6.53 per share on August 6, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in C3.ai, Inc. of Class Action Lawsuit and Upcoming Deadlines - AI

NEW YORK, Pomerantz LLP announces that a class action lawsuit has been filed against C3.ai, Inc.  (“C3” or the “Company”) (NYSE: AI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether C3 and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until October 21, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired C3 securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com        

[Click here for information about joining the class action]

On August 8, 2025, C3 announced disappointing preliminary financial results for the first quarter of fiscal 2026 and reduced its revenue guidance for the full fiscal year 2026.  The Company attributed its poor sales results and lowered guidance on “the reorganization with new leadership” and the health ailments of its Chief Executive Officer.  

On this news, C3’s stock price fell $5.66 per share, or 25.58%, to close at $16.47 per share on August 11, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Snap, Inc. of Class Action Lawsuit and Upcoming Deadlines - SNAP

NEW YORK, Pomerantz LLP announces that a class action lawsuit has been filed against Snap, Inc. (“Snap” or the “Company”) (NYSE: SNAP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether Snap and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until October 20, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Snap securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com        

[Click here for information about joining the class action]

On August 5, 2025, Snap announced its financial results for the second quarter of fiscal year 2025, disclosing a deceleration in advertising revenue growth.  The Company attributed the slowdown to “an issue related to our ad platform, the timing of Ramadan, and the effects of the de minimis changes.” 

On this news, Snap’s stock price fell $1.61 per share, or 17.15%, to close at $7.78 per share on August 6, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in PubMatic, Inc. of Class Action Lawsuit and Upcoming Deadlines - PUBM

NEW YORK, Pomerantz LLP announces that a class action lawsuit has been filed against PubMatic, Inc. (“PubMatic” or the “Company”) (NASDAQ: PUBM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether PubMatic and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until October 20, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired PubMatic securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com        

[Click here for information about joining the class action]

On August 11, 2025, PubMatic issued a press release announcing its financial results for the second quarter of 2025.  Therein, the Company’s Chief Financial Officer Steven Pantelick revealed that PubMatic’s outlook reflects “a reduction in ad spend from one of [its] top DSP [demand side platform] partners.”  The Company’s Chief Executive Officer Rajeev Goel further revealed that a “top DSP buyer” had “shifted a significant number of clients to a new platform that evaluates inventory differently,” causing significant headwinds.  Goel stated that, in response to the inventory valuation change, PubMatic would “need to do a better job . . . to prioritize across all the hundreds of billions of daily ad impressions that we have, which subset of those impressions that we send to this DSP.” 

On this news, PubMatic’s stock price fell $2.23 per share, or 21.1%, to close at $8.34 per share on August 12, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in aTyr Pharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATYR

NEW YORK, Pomerantz LLP announces that a class action lawsuit has been filed against aTyr Pharma, Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether aTyr and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until December 8, 2025, to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired aTyr securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.         

[Click here for information about joining the class action]

On September 15, 2025, aTyr hosted an investor call announcing that the EFZO-FIT study—a Phase 3, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of intravenous Efzofitimod in patients with pulmonary sarcoidosis—did not meet its primary endpoint in change from baseline in mean daily OSC dose at week 48.  Additionally, aTyr announced that the Company’s next step was to engage with the U.S. Food and Drug Administration to determine a path forward, given the disappointing topline results.   

On this news, aTyr’s stock price fell $5.01 per share, or 83.17%, to close at $1.01 per share on September 15, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes.   

Pomerantz Law Firm Announces the Filing of a Class Action Against Cepton, Inc. and Certain Officers – CPTN

NEW YORK, Pomerantz LLP announces that a class action lawsuit has been filed against Cepton, Inc.  (“Cepton” or the “Company”) (NASDAQ: CPTN) and certain officers.   The class action, filed in the United States District Court for the Northern District of California, and docketed under 25-cv-08571, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or sold shares of Cepton common stock between July 29, 2024 and January 6, 2025, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

If you are an investor who purchased or otherwise acquired Cepton securities during the Class Period, you have until December 8, 2025, to ask the Court to appoint you as Lead Plaintiff for the class.  A copy of the Complaint can be obtained at www.pomerantzlaw.com.   To discuss this action, contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.   

[Click here for information about joining the class action]

Prior to the Company’s merger with Koito Manufacturing Co., Ltd. (“Koito”) (the “Koito Acquisition” or the “Merger”) (as described below), Cepton was an electronics company focused on the deployment of high performance, mass-market light detection and ranging (“lidar”) technologies to deliver safety and autonomy across the Automotive and Smart Infrastructure markets.  The Company offered near-range lidars, long-range lidars and ultra-long-range lidars, automotive software and smart lidar systems that include its perception software.

As of July 2023, Koito, a Japanese manufacturer of automotive lighting equipment, had invested $200 million in Cepton in exchange for common and preferred stock amounting to 30.1% of Cepton’s voting power on an as-converted basis and held two out of seven seats on the Company’s Board of Directors (the “Board”).  In October 2023, Koito requested that the Board form a special committee to negotiate a potential transaction with Koito.  In December 2023, Koito announced a bid to acquire Cepton for $3.17 per share in cash in a going private transaction.

In July 2024, Cepton announced that it had accepted Koito’s bid to acquire all of the Company’s outstanding capital stock not owned by Koito for $3.17 per share in an all-cash transaction.  According to Cepton, the Koito Acquisition would purportedly “complement Koito’s existing sensor technology roadmap, while providing Cepton with the financial stability and scalability that are crucial to the commercialization of its lidar technology.” 

The Koito Acquisition closed on January 7, 2025, at which point all outstanding Cepton shareholders received $3.17 per share of Cepton common stock in cash.  In a press release issued that same day, Cepton stated that the Merger “marks a strategic milestone in the industrialization of Cepton’s cutting-edge lidar technology, combining the strengths of both companies to reshape future mobility” and “[s]upported by Koito’s world-renowned automotive expertise, Cepton will continue to commercialize its lidar solutions with a strong focus on quality, reliability and sustainability.” 

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and compliance policies.  Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Cepton had received a credible third-party bid valuing Cepton at more than double the Koito Acquisition; (ii) Cepton’s Board of Directors failed to meaningfully explore the foregoing offer and failed to disclose its terms when recommending that Cepton’s shareholders approve the Koito Acquisition; (iii) consequently, Cepton’s shareholders were deprived of the opportunity to meaningfully consider whether to accept or reject the Koito Acquisition; and (iv) as a result, Defendants’ public statements were materially false and misleading at all relevant times.

Investors began to learn the truth four months after the Merger closed when, in May 2025, former Cepton shareholders filed two verified class action complaints in the Court of Chancery for the State of Delaware against, among others, Cepton and certain of the Company’s executive officers, in connection with the Koito Acquisition.   In July 2025, the foregoing actions were consolidated and restyled as In re Cepton, Inc. Stockholder Litigation, Case No. 2025-0519-LWW (the “Delaware Action”).  Then, in September 2025, a redacted version of an amended consolidated class action complaint (the “Amended Complaint”) filed in the Delaware Action became publicly available.  The Amended Complaint followed a review of books and records produced by Cepton in response to plaintiffs’ demands made under 8 Del. C. § 220. The Amended Complaint alleges that Cepton’s Board agreed to the Koito Acquisition “at a price that was so unreasonable as to shock the conscience, and then pitched the grossly unfair deal to stockholders with a Proxy that concealed critical facts.” Moreover, the Amended Complaint alleges that “the Proxy failed to disclose Cepton’s receipt of—and the Board’s utter failure to explore—a credible third-party bid valuing Cepton at more than double” the Koito Acquisition.  The Amended Complaint further alleges that Cepton’s Chief Executive Officer Defendant Jun Pei was subject to conflicts in his negotiations with Koito and encouraged the Board to recommend accepting the Koito Acquisition so as to protect his own personal economic interests at the expense of Cepton’s stockholders.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes.

Pomerantz Law Firm Announces the Filing of a Class Action on Behalf of Investors in the Securities of Spirit Aviation Holdings, Inc. – FLYYQ

NEW YORK, Pomerantz LLP announces that a class action lawsuit has been filed on behalf of investors in the securities of Spirit Aviation Holdings, Inc. (“Spirit” or the “Company”) (OTCMKTS: FLYYQ).   The class action, filed in the United States District Court for the Southern District of Florida, and docketed under 25-cv-61959, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Spirit securities between May 28, 2025 and August 29, 2025, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against certain of the Company’s top officials.

If you are an investor who purchased or otherwise acquired Spirit securities during the Class Period, you have until December 1, 2025, to ask the Court to appoint you as Lead Plaintiff for the class.  A copy of the Complaint can be obtained at www.pomerantzlaw.com.   To discuss this action, contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.   

[Click here for information about joining the class action] 

    Spirit is the parent company of Spirit Airlines, LLC, an ultra-low-cost American airline that provides passenger air transportation services for destinations throughout the United States (“U.S.”), Latin America, and the Caribbean.

    In November 2024, Spirit’s predecessor entity, Spirit Airlines, Inc. (“Former Spirit”) and its subsidiaries (collectively with Former Spirit, the “Corporate Debtors”) filed a voluntary petition for Chapter 11 bankruptcy protection after years of mounting losses and increased competition, among other issues.

    In March 2025, the Corporate Debtors satisfied the conditions precedent to consummation of a pre-arranged Chapter 11 plan of reorganization (the “Plan of Reorganization”), whereby, inter alia, the Corporate Debtors emerged from Chapter 11 bankruptcy protection.  In connection with the Plan of Reorganization, Former Spirit completed a corporate reorganization pursuant to which Spirit became the new parent company of the Corporate Debtors, with Former Spirit becoming a wholly owned subsidiary of Spirit and converted from a Delaware corporation to a Delaware limited liability company.

    In late April 2025, Spirit announced that its common stock had been approved for listing on the NYSE American (“NYSE”), with public trading to begin on April 29, 2025 under the ticker symbol “FLYY.”

    Thereafter, at all relevant times, Defendants touted their purported plan to enhance Spirit’s liquidity, financial condition, and business operations, as well as the purported positive impacts these measures were having the Company’s business and financial results.  In so doing, Defendants indicated to investors and the market that Spirit’s business had emerged from bankruptcy protection on improved financial footing with the requisite corporate strategy and means to operate as a publicly traded company.

    The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding Spirit’s business, operations, and prospects.  Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Spirit was at substantial risk of being unable to meet certain of its debt and other financial obligations; (ii) Spirit was also at substantial risk of being forced to file for Chapter 11 bankruptcy protection within a mere matter of months; (iii) accordingly, Defendants had overstated enhancements to Spirit’s financial condition, liquidity, and overall business and operations, while simultaneously downplaying the negative impacts of adverse market conditions on the same; and (iv) as a result, Defendants’ public statements were materially false and misleading at all relevant times.

    On August 11, 2025, Spirit filed a quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission (“SEC”) for the period ended June 30, 2025.  Therein, Defendants disclosed that “there is substantial doubt as to the Company’s ability to continue as a going concern within 12 months[,]” citing, inter alia, “adverse market conditions” and “minimum liquidity covenants in the Company’s debt obligations and credit card processing agreement [that] require financial results to improve at a rate faster than what the Company is currently anticipating.” 

    On this news, Spirit’s stock price fell $1.44 per share, or 40.68%, to close at $2.10 per share on August 12, 2025.

    That same month, on August 29, 2025, Spirit issued a press release wherein Defendants disclosed, inter alia, that “the Company has filed voluntary petitions for Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York” and that “[t]he [Company’s] shares are expected to be cancelled and have no value as part of Spirit’s restructuring.”

    On the next trading day, September 2, 2025, the NYSE suspended trading of Spirit’s common stock.  As Spirit explained in an SEC filing on September 3, 2025, the Company had received a notice from the regulatory staff of the NYSE (the “NYSE Regulation”) on September 2, 2025, wherein the NYSE Regulation notified Spirit that it “had determined to commence proceedings to delist the common stock . . . of the Company” and, accordingly, trading in Spirit’s common stock “was suspended immediately on September 2, 2025.”

    Following the foregoing disclosures and developments, Spirit’s stock price fell $0.71 per share, or 58.2%, to close at $0.51 per share on September 3, 2025—the first day that the Company’s common stock began trading on the over-the-counter market under the ticker symbol “FLYYQ.”

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com

Attorney advertising.  Prior results do not guarantee similar outcomes. 

Pomerantz Law Firm Announces the Filing of a Class Action Against Jasper Therapeutics, Inc. and Certain Officers – JSPR

NEW YORK, Pomerantz LLP announces that a class action lawsuit has been filed against Jasper Therapeutics, Inc.  (“Jasper” or the “Company”) (NASDAQ: JSPR) and certain officers.   The class action, filed in the United States District Court for the Northern District of California, and docketed under 25-cv-08010, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Jasper securities between November 30, 2023 and July 3, 2025, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

If you are an investor who purchased or otherwise acquired Jasper securities during the Class Period, you have until November 18, 2025 to ask the Court to appoint you as Lead Plaintiff for the class.  A copy of the Complaint can be obtained at www.pomerantzlaw.com.   To discuss this action, contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.   

[Click here for information about joining the class action]

Jasper, a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (“CSU”), Chronic Inducible Urticaria (“CIndU”), and Asthma.  The Company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor (“SCF”) from binding to and signaling through the CD117 (“c-Kit”) receptor on mast and stem cells.  According to Jasper, the “SCF/c-Kit pathway is a survival signal for mast cells and [the Company] believe[s] that blocking this pathway may lead to depletion of these cells throughout the body, including in the lungs and in the skin, which could lead to significant clinical benefit for patients with mast-cell driven diseases such as asthma and chronic urticarias” and “[t]o that end, [Jasper is] focusing on advancing a portfolio of clinical programs in mast cell driven diseases.”  In 2024, to “strengthen [its] balance sheet and support development of briquilimab,” Jasper completed an oversubscribed $50 million financing “with a syndicate of leading life science investors,” purportedly “extending [its] cash runway through the third quarter of 2025.”

In November 2023, the Company commenced a Phase 1b/2a clinical study of subcutaneous briquilimab for the treatment of CSU (the “BEACON Study”).  When announcing the first patient dosing in the BEACON Study, Jasper’s Chief Executive Officer Defendant Ronald Martell stated, in relevant part, that he was “confident in the ability of our clinical organization to continue to execute at a high level as we advance briquilimab into clinical trials in CIndU and other mast cell-driven diseases.”  In December 2024, the Company commenced a Phase 1b/2a clinical study evaluating briquilimab in allergic asthma (the “ETESIAN Study”).  In addition, Jasper has attempted to develop briquilimab as a one-time conditioning therapy for severe combined immunodeficiency (“SCID”) patients undergoing a second stem cell transplant.

Under the Drug Supply Chain Security Act —a law enacted by Congress in 2013 designed to improve and ensure the safety of the U.S pharmaceutical supply chain—all prescription drugs must be labeled with a unique product identifier that includes, among other things, a “lot number.”  Drug “lots” are batches of a product that are manufactured, processed, packaged, or stored under the same conditions.  If a medication is compromised, pharmaceuticals companies can use lot numbers to trace the affected batches and alert healthcare providers.

According to the Company, “[t]he manufacture of pharmaceuticals is subject to extensive [current Good Manufacturing Practices (“cGMP”)] regulations, which impose various procedural and documentation requirements and govern all areas of record keeping, production processes and controls, personnel and quality control.”  Because Jasper does not currently own or operate any manufacturing facility, the Company relies on third-party contract manufacturing organizations to produce its drug candidates in purported “accordance with cGMP regulations for use in [its] clinical studies.”

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and compliance policies.  Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Jasper lacked the controls and procedures necessary to ensure that the third-party manufacturers on which it relied were manufacturing products in full accordance with cGMP regulations and otherwise suitable for use in clinical trials; (ii) the foregoing failure increased the risk that results of ongoing studies would be confounded, thereby negatively impacting the regulatory and commercial prospects of the Company’s products, including briquilimab; (iii) the foregoing increased the likelihood of disruptive cost-reduction measures; (iv) accordingly, the Company’s business and/or financial prospects, as well as briquilimab’s clinical and/or commercial prospects, were overstated; and (v) as a result, Defendants’ public statements were materially false and misleading at all relevant times.

On July 7, 2025, Jasper issued a press release reporting updated data from the BEACON Study.  The press release stated that “[r]esults from the 240mg Q8W and the 240mg followed by 180mg Q8W dose cohorts appear to be confounded by an issue with one drug product lot used in those cohorts, with 10 of the 13 patients dosed with drug from the lot in question,” that “[t]he Company is investigating the drug product lot in question and expects to have the results of that investigation in the coming weeks,” and that Jasper was “taking steps to ensure that drug product from the lot in question is returned to the Company and that sites have drug product from other lots to continue dosing.”  Further, the press release revealed that the Company “has also determined that the drug product lot in question was used to treat participants enrolled in the ETESIAN [Study]. As a result, and in order to focus resources on advancing briquilimab in CSU, the Company is halting the study and pausing development in asthma.”  Finally, the press release stated that “the Company is halting development in SCID” and, contrary to its prior representation of having a strong balance sheet and a cash runway extending “through the third quarter of 2025,” that Jasper “will be implementing a number of other cost cutting measures including a potential restructuring, to extend runway and reduce expenses.”

On this news, Jasper’s stock price fell $3.73 per share, or 55.1%, to close at $3.04 per share on July 7, 2025.

Market analysts were quick to comment on the Company’s announcement.  For example, on July 7, 2025, BMO Capital Markets published a report downgrading Jasper to market perform and lowering its price target from $6.77 per share to $4.00 per share (the “BMO Report”).  The BMO Report stated, in relevant part, that “potential Briquilimab drug lot issues, coupled with existing uncertainty around dose-response [], will pressure the [Jasper] story moving forward” given, among other things, Jasper’s “financing overhang” and market competition.

After the end of the Class Period, on July 9, 2025, the Company issued a press release entitled “Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash Runway.”  The press release revealed that Jasper was reducing its workforce by approximately 50%, that “[i]n order to focus resources on the development of briquilimab in chronic urticaria, Jasper is halting its other clinical and preclinical programs,” and that Defendant Edwin Tucker was departing his role as the Company’s Chief Medical Officer effective August 1, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com

Attorney advertising.  Prior results do not guarantee similar outcomes. 

Pomerantz Law Firm Announces the Filing of a Class Action Against Fluor Corporation and Certain Officers – FLR

NEW YORK, Pomerantz LLP announces that a class action lawsuit has been filed against Fluor Corporation (“Fluor” or the “Company”) (NYSE: FLR) and certain officers.   The class action, filed in the United States District Court for the Northern District of Texas, Dallas Division, and docketed under 25-cv-08010, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Fluor securities between February 18, 2025 and July 31, 2025, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

If you are an investor who purchased or otherwise acquired Fluor securities during the Class Period, you have until November 14, 2025, to ask the Court to appoint you as Lead Plaintiff for the class.  A copy of the Complaint can be obtained at www.pomerantzlaw.com.   To discuss this action, contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.   

[Click here for information about joining the class action]

                Fluor provides engineering, procurement, and construction (“EPC”), fabrication and modularization, and project management services worldwide.  The Company operates through three segments: Urban Solutions, Energy Solutions, and Mission Solutions. 

Throughout 2024 and the first quarter of 2025, Fluor’s Urban Solutions segment accounted for the largest portion of the Company’s revenue and profit.  The Urban Solutions segment offers EPC and project management services to the advanced technologies and manufacturing, life sciences, mining and metals, and infrastructure industries, as well as provides professional staffing services. The Company’s infrastructure projects in this segment include work on, inter alia, the Gordie Howe International Bridge (“Gordie Howe”), as well as the Interstate 365 Lyndon B. Johnson (“I-635/LBJ”) and Interstate 35E (“I-35”) highways in Texas.

In February 2025, Fluor provided financial guidance for the full year (“FY”) of 2025, including adjusted EBITDA of $575 million to $675 million and adjusted earnings per share (“EPS”) of $2.25 per share to $2.75 per share.  Defendants reaffirmed the foregoing financial guidance in May 2025, notwithstanding their acknowledgement of the potential negative impacts of ongoing economic uncertainty on Fluor’s business resulting from trade tensions and other market conditions.  Contemporaneously, Defendants touted, inter alia, the purported health and stability of Fluor’s and its customers’ operations and the strength of the Company’s risk mitigation strategy, both for itself and its clients.

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding Fluor’s business, operations, and prospects.  Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) costs associated with the Gordie Howe, I-635/LBJ, and I-35 projects were growing because of, inter alia, subcontractor design errors, price increases, and scheduling delays; (ii) the foregoing, as well as customer reduction in capital spending and client hesitation around economic uncertainty, was having, or was likely to have, a significant negative impact on the Company’s business and financial results; (iv) accordingly, Fluor’s financial guidance for FY 2025 was unreliable and/or unrealistic, the effectiveness of the Company’s risk mitigation strategy was overstated, and the impact of economic uncertainty on the Company’s business and financial results was understated; and (v) as a result, Defendants’ public statements were materially false and misleading at all relevant times.

On August 1, 2025, Fluor issued a press release reporting its financial results for the second quarter (“Q2”) of 2025.  Among other results, the press release reported Q2 non-GAAP EPS of $0.43, missing consensus estimates by $0.13, and revenue of $3.98 billion, representing a 5.9% year-over-year decline and missing consensus estimates by $570 million.  Defendants blamed these disappointing results on, inter alia, growing costs in multiple infrastructure projects due to subcontractor design errors, price increases, and scheduling delays, as well as reduced capital spending by customers.  The same press release also provided a negatively revised financial outlook for FY 2025, guiding to adjusted EBITDA of $475 million to $525 million, down significantly from Defendants’ prior guidance of $575 million to $675 million, and adjusted EPS of $1.95 per share to $2.15 per share, down significantly from Defendants’ prior guidance of $2.25 per share to $2.75 per share, citing “client hesitation around economic uncertainty and its impact on new awards and project delays and results for the quarter[.]”

The same day, Fluor hosted a conference call with investors and analysts to discuss the Company’s Q2 2025 financial results.  During that call, the Company’s Chief Executive Officer, Defendant James R. Breuer, disclosed that the infrastructure projects that had negatively impacted Fluor’s Q2 2025 results were the Gordie Howe, I-635/LBJ, and I-35 projects.

Following the foregoing disclosures, Fluor’s stock price fell $15.35 per share, or 27.04%, to close at $41.42 per share on August 1, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com

Attorney advertising.  Prior results do not guarantee similar outcomes.